U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06866041) titled 'Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance' on March 04.
Brief Summary: This study aims to identify patients with low-risk prostate cancer (ISUP Grade Group 1) eligible for active surveillance who are at higher risk of upgrading to ISUP Grade Group 2 or higher at confirmatory biopsy one year after diagnosis. Patients with low-risk ISUP GG1 tumors will be selected and undergo:
* PSMA PET with calculation of SUVmax and PRIMARY-Likert score
* Whole Exome Sequencing (WES) analysis on diagnostic prostate biopsies
* Immunohistochemistry on diagnostic prostate biopsies
* Confirmatory...